304 related articles for article (PubMed ID: 8282823)
41. Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency.
Naves-Díaz M; Carrillo-López N; Rodríguez-Rodríguez A; Braga S; Fernández-Coto T; Lopez-Novoa JM; López-Hernández F; Cannata-Andía JB
Menopause; 2010 Jul; 17(4):766-71. PubMed ID: 20386345
[TBL] [Abstract][Full Text] [Related]
42. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
43. Effects of the antiestrogenic environmental pollutant 3,3',4,4', 5-pentachlorobiphenyl (PCB #126) in rat bone and uterus: diverging effects in ovariectomized and intact animals.
Lind PM; Eriksen EF; Sahlin L; Edlund M; Orberg J
Toxicol Appl Pharmacol; 1999 Feb; 154(3):236-44. PubMed ID: 9931283
[TBL] [Abstract][Full Text] [Related]
44. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
45. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Carthew P; Edwards RE; Nolan BM
Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929
[TBL] [Abstract][Full Text] [Related]
46. Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels.
Lundeen SG; Carver JM; McKean ML; Winneker RC
Endocrinology; 1997 Apr; 138(4):1552-8. PubMed ID: 9075715
[TBL] [Abstract][Full Text] [Related]
47. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.
Unkila M; Kari S; Yatkin E; Lammintausta R
J Steroid Biochem Mol Biol; 2013 Nov; 138():107-15. PubMed ID: 23665515
[TBL] [Abstract][Full Text] [Related]
48. The bone-specific estrogen centchroman inhibits osteoclastic bone resorption in vitro.
Hall TJ; Nyugen H; Schaueblin M; Fournier B
Biochem Biophys Res Commun; 1995 Nov; 216(2):662-8. PubMed ID: 7488162
[TBL] [Abstract][Full Text] [Related]
49. LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34).
Sato M; Zeng GQ; Rowley E; Turner CH
Endocrinology; 1998 Nov; 139(11):4642-51. PubMed ID: 9794476
[TBL] [Abstract][Full Text] [Related]
50. Antagonism of estrogen action with a new benzothiophene derived antiestrogen.
Black LJ; Jones CD; Falcone JF
Life Sci; 1983 Feb; 32(9):1031-6. PubMed ID: 6827921
[TBL] [Abstract][Full Text] [Related]
51. Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats.
Meli R; Pacilio M; Raso GM; Esposito E; Coppola A; Nasti A; Di Carlo C; Nappi C; Di Carlo R
Endocrinology; 2004 Jul; 145(7):3115-21. PubMed ID: 15059958
[TBL] [Abstract][Full Text] [Related]
52. Prenylflavonoids: a new class of non-steroidal phytoestrogen (Part 2). Estrogenic effects of 8-isopentenylnaringenin on bone metabolism.
Miyamoto M; Matsushita Y; Kiyokawa A; Fukuda C; Iijima Y; Sugano M; Akiyama T
Planta Med; 1998 Aug; 64(6):516-9. PubMed ID: 9741296
[TBL] [Abstract][Full Text] [Related]
53. Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat.
Sibonga JD; Lotinun S; Evans GL; Pribluda VS; Green SJ; Turner RT
Endocrinology; 2003 Mar; 144(3):785-92. PubMed ID: 12586754
[TBL] [Abstract][Full Text] [Related]
54. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing.
Buelke-Sam J; Bryant HU; Francis PC
Reprod Toxicol; 1998; 12(3):217-21. PubMed ID: 9628546
[TBL] [Abstract][Full Text] [Related]
55. Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation.
Li B; Yu S
Biol Pharm Bull; 2003 Jun; 26(6):780-6. PubMed ID: 12808286
[TBL] [Abstract][Full Text] [Related]
56. Effects of LY-117018 HCl on bone remodeling and mineral density in the oophorectomized rat.
Curiel MD; Calero JA; Guerrero R; Gala J; Gazapo R; de la Piedra C
Am J Obstet Gynecol; 1998 Feb; 178(2):320-5. PubMed ID: 9500493
[TBL] [Abstract][Full Text] [Related]
57. Possible antiestrogenic properties of chloro-s-triazines in rat uterus.
Tennant MK; Hill DS; Eldridge JC; Wetzel LT; Breckenridge CB; Stevens JT
J Toxicol Environ Health; 1994 Oct; 43(2):183-96. PubMed ID: 7932848
[TBL] [Abstract][Full Text] [Related]
58. Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats.
Jimenez MA; Magee DE; Bryant HU; Turner RT
Endocrinology; 1997 May; 138(5):1794-800. PubMed ID: 9112370
[TBL] [Abstract][Full Text] [Related]
59. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.
Yang NN; Bryant HU; Hardikar S; Sato M; Galvin RJ; Glasebrook AL; Termine JD
Endocrinology; 1996 May; 137(5):2075-84. PubMed ID: 8612550
[TBL] [Abstract][Full Text] [Related]
60. A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.
Geiser AG; Hummel CW; Draper MW; Henck JW; Cohen IR; Rudmann DG; Donnelly KB; Adrian MD; Shepherd TA; Wallace OB; McCann DJ; Oldham SW; Bryant HU; Sato M; Dodge JA
Endocrinology; 2005 Oct; 146(10):4524-35. PubMed ID: 16002528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
